Breaking News

Immunai, BMS Join Forces to Advance Clinical Development

Immunai will support BMS’s clinical development efforts by applying its AI-powered operating system, AMICA-OS.

Author Image

By: Charlie Sternberg

Associate Editor

Immunai, an AI biotech company specializing in mapping the human immune system, has announced a strategic collaboration with Bristol Myers Squibb Company (BMS), under which Immunai will support BMS’s clinical development efforts by applying its AI-powered operating system, AMICA-OS, to gain deeper insight into patient immune responses and inform clinical decision-making. The collaboration will leverage Immunai’s immune system AI models and infrastructure within AMICA-OS to analyze high-dimens...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters